LOGIN
ID
PW
MemberShip
2025-09-09 23:08
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Opinion
[Reporter's View] Fostering BD talent requires tech¡¤strateg
by
Whang, byung-woo
Jun 12, 2025 06:04am
Recently, the role of business development (BD) in the pharmaceutical and biotech industry has been rapidly advancing. Previously regarded simply as a sales task, BD changed to one of the core strategic teams that oversees the success of new drug development. BD is responsible for key discovery and execution of various opportunities for n
Opinion
[Reporter's View] Biotech policy must be consistent
by
Jun 4, 2025 06:17am
What's the most critical factor in corporate management? It's challenging to pinpoint whether it's capital, talent, or technology. However, for all these elements to function, a prerequisite must be established: predictability. A company must be able to foresee the future to invest and endure risks to recruit and conduct R&D. South Korea
Opinion
[Reporter's View] Addressing drug shortage, healthcare
by
Lee, Jeong-Hwan
May 30, 2025 05:57am
Ahead of Korea's early presidential election, scheduled for June 3, leading candidates have prioritized pledges to strengthen government support for essential medicines¡¤address drug shortages. Lee Jae-myung, the candidate for the Democratic Party of Korea, included the resolution of a supply shortage of essential medicines in his top 10
Opinion
[Reporter¡¯s View] Reimbursing the only RET-targeted therapy
by
Eo, Yun-Ho
May 29, 2025 05:52am
News of a new drug failing to be listed for insurance reimbursement always upsets patients. The blow is even harder when it is the only treatment option available. Such was the case in 2023 when the National Health Insurance Service and Lilly failed to reach an agreement on the price of the RET-targeted anticancer drug Retevmo (selpercati
Opinion
[Reporter's View] 'Samsung Epis' as independent firm
by
Whang, byung-woo
May 23, 2025 05:51am
Samsung Biologics officially announced on May 22 that its shareholders determined to conduct a spinoff of Samsung Bioepis and establish 'Samsung Epis Holdings.' The business independence of Samsung Bioepis, which expanded its focus on biosimilars, was conducted earlier than anticipated. It has been two years since Samsung Biologics acquire
Opinion
[Reporter's View] Strengthening GMP for sterile drugs
by
Kim, Jin-Gu
May 19, 2025 05:56am
The government has reaffirmed its existing position on strengthening GMP standards for sterile finished drug products in December. The Ministry of Food and Drug Safety recently met with sterile drug factory managers and stated that there will be no postponement of the enforcement of the ¡°Regulations on Drug Manufacturing and Quality Control
Opinion
[Reporter's View] Korea¡¯s vaccination space: ups and downs
by
Eo, Yun-Ho
May 15, 2025 06:23am
Vaccines are at the forefront of localized pharmaceuticals in Korea. Leading domestic companies such as GC Biopharma and SK Bioscience are now responsible for vaccine production and supplying preventive vaccines for various diseases, including influenza. The commercialization of so-called ¡°premium homegrown vaccines,¡± such as pneumococc
Opinion
[Reporter's View] USIM data leakage incident is a warning
by
Kim, Jin-Gu
May 2, 2025 05:55am
The SKT USIM data leakage incident has spread anxiety throughout society. Previously, there have been countless personal data security breaches, but the latest incident is considered differently. The scale of the expected damage is so large that it¡¯s hard to estimate. Long lines have formed in front of SKT stores as people wait to replace th
Opinion
[Reporter¡¯s View] Consideration in legislating telemedicine
by
Lee, Jeong-Hwan
Apr 30, 2025 06:07am
Following the presidential election on June 3, which will determine the next president and new administration, one of the most urgent healthcare policies that would need to be addressed is ¡®non-face-to-face treatment,¡¯ or telemedicine. Currently, two bills to formalize telemedicine, which is currently under pilot programs, are pending i
Opinion
[Reporter's View] Prescribing pre-reviewed new drugs
by
Eo, Yun-Ho
Apr 30, 2025 06:06am
New drugs that patients long-awaited are being reimbursed, but no hospitals are prescribing them. There have been various attempts at improving the system, but an issue related to new drug access remains unresolved in South Korea. Public petitions for reimbursement of a particular new drug are frequently listed, and more patient organi
1
2
3
4
5
6
7
8
9
10
>